Anzeige
Mehr »
Login
Sonntag, 13.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Angehender Nickelproduzent mit 439 Mio. $ Gewinn pro Jahr!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PSNF ISIN: US6300873022 Ticker-Symbol: NV3P 
Tradegate
11.06.21
17:04 Uhr
3,492 Euro
+0,250
+7,71 %
Branche
Nanotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
NANOVIRICIDES INC Chart 1 Jahr
5-Tage-Chart
NANOVIRICIDES INC 5-Tage-Chart
RealtimeGeldBriefZeit
3,5523,74011.06.

Aktuelle News zur NANOVIRICIDES Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
17.05.NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards IND879SHELTON, CT / ACCESSWIRE / May 17, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
14.05.NANOVIRICIDES, INC. - 10-Q, Quaterly Report2
NANOVIRICIDES Aktie jetzt für 0€ handeln
04.05.XFRA NEW INSTRUMENTS AVAILABLE ON XETRA - 04.05.20211.866The following instruments on XETRA do have their first trading 04.05.2021 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag am 04.05.2021 Aktien 1 NO0010895568 Airthings AS 2 ES0105148003...
► Artikel lesen
09.03.NanoViricides reports strong pre-clinical data for COVID-19 drugs5
09.03.NanoViricides, Inc. Pan-coronavirus COVID-19 Drug Candidates Are Highly Effective in Pre-clinical Animal Studies in Support of FDA Pre-IND Application1.188SHELTON, CT / ACCESSWIRE / March 9, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
03.03.Ovid Therapeutics, KemPharm leads healthcare gainers; Vir Biotechnology, NanoViricides among major losers17
02.03.Mid-Day Market Update: Nasdaq Down 100 Points; NanoViricides Shares Spike Higher8
02.03.NanoViricides, CHF Solutions leads healthcare gainers; FibroGen, Neuronetics among major losers18
02.03.NanoViricides Reports 'Strong Effectiveness' for COVID Drugs11
02.03.NNVC Stock: The COVID-19 Drug News That Has NanoViricides Rocketing Today10
02.03.The Daily Biotech Pulse: Roxadustat Delay For FibroGen, AstraZeneca, Decision Day For KemPharm, NanoViricides Jumps On COVID-19 Drug Data37
02.03.NanoViricides shares rally 29% on effectiveness of COVID-19 drug candidates in cell culture studies16
02.03.NanoViricides, Inc. Pan-coronavirus Clinical Drug Candidates for the Treatment of COVID-19 Are Highly Effective in Pre-clinical Cell Culture Studies Performed in Preparation of FDA Pre-IND Application731SHELTON, CT / ACCESSWIRE / March 2, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a leader in the development of highly effective antiviral therapies based on a novel nanomedicine...
► Artikel lesen
17.02.NanoViricides reports FQ2 results9
17.02.NanoViricides, Inc.: NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2020 - Has Sufficient Cash, Coronavirus Drug Candidate Safe in GLP Safety Toxicology Moving Towards IND1.666SHELTON, CT / ACCESSWIRE / February 17, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines...
► Artikel lesen
16.02.NANOVIRICIDES, INC. - 10-Q, Quaterly Report2
08.02.NanoViricides' Broad-Spectrum Antiviral Drug Candidate Shows Encouraging Action In Preclinical Studies For COVID-194
08.02.NanoViricides's anti-coronavirus candidate was well tolerated in animal studies4
08.02.NanoViricides, Inc.: NanoViricides's Broad-Spectrum Antiviral Drug Candidate for the Treatment of COVID-19 Infections was Well Tolerated in GLP and non-GLP Animal Safety Studies1.451SHELTON, CT / ACCESSWIRE / February 8, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based...
► Artikel lesen
27.01.Broad-Spectrum Direct Antiviral Nanomedicine Should Remain Effective Against COVID-19 Virus Variants, Says NanoViricides, Inc.'s President, Dr. Anil Diwan979SHELTON, CT / ACCESSWIRE / January 27, 2021 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective broad-spectrum antiviral therapies based...
► Artikel lesen
Seite:  Weiter >>
35 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,3